Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aphria Inc. APHA

Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints of federal prohibition. It has some U.S. exposure through the acquisition of SweetWater, a craft brewer


NDAQ:APHA - Post by User

Bullboard Posts
Comment by ThisIsNoGameon Nov 25, 2018 9:59am
135 Views
Post# 29018677

RE:Speculation

RE:Speculation *****. Thankyou Skyplt. Appreciate your posts!

.
skyplt wrote: I will leave the speculation about “deal or no deal” to those apparently in the know.  I picture ProfC with a briefcase full of money making Howie Mandel type cryptic references to how much money is actually inside.

My views pertain to the various political and macroeconomic forces in play.

UK PM got EU approval for Brexit.  I believe there will be a vote in UK Parliament on 11 Dec.  50/50 regarding whether it passes.  I believe this will have an impact on market sentiment.

USA/China trade talk next week will turn G20 into a sideshow.  We really need a Presidential handshake here.

Interest rates should be held steady for a bit until the impact of recent ones is fully understood.

The mail needs to start moving.

Health Canada needs to make some approvals.

APHA should announce solid numbers in January.  I also think they should be putting out a NR confirming they are still supporting medical users.  This has to do with trust and not substituting short  term profits at the sake of their long term game which is the pharmaceutical side as some others in the sector are choosing.  On that note, once they get Germany up and running they will be hitting international targets.  I still believe medical will trump recreational on the international stage.

Indeed, any sort of deal would sweeten the pot.  It strikes me as though 12 dollars is the price the market has determined APHA is without a deal and all the bad macroeconomic news as well.  As these  issues get resolved the price will ratchet up.  I certainly hope those who held fast during this drop will start to see gains.  It does seem logical that APHA will begin to rise...but then, I thought it was headed to the mid twenties in October.  Everyone must do their own diligence and decide accordingly.  We are all too familiar with the dangers of spreading rumours of speculative deals.  I hope one happens, but APHA stock does not need one to thrive.


Bullboard Posts